The global pulmonary fibrosis biomarkers market is likely to reach US$ 6.2 billion in value by 2033, with a projected market size of US$ 4.1 billion in 2023 and an anticipated CAGR of 4.2% throughout the forecast period. Key to this growth is the rapid advancement in pulmonary fibrosis biomarkers, enabling the discovery, validation, and clinical translation of new biomarkers. High-throughput...